DK0830141T3 - Forbedrede virusvacciner - Google Patents

Forbedrede virusvacciner

Info

Publication number
DK0830141T3
DK0830141T3 DK96913234T DK96913234T DK0830141T3 DK 0830141 T3 DK0830141 T3 DK 0830141T3 DK 96913234 T DK96913234 T DK 96913234T DK 96913234 T DK96913234 T DK 96913234T DK 0830141 T3 DK0830141 T3 DK 0830141T3
Authority
DK
Denmark
Prior art keywords
virus
strains
inactivated
neuraminidase
hemagglutinin
Prior art date
Application number
DK96913234T
Other languages
English (en)
Inventor
Gale Eugene Smith
James T Mattews
Edwin D Kilbourne
Bert E Johannson
Bethanie E Wilkinson
Andrei I Voznesensky
Craig S Hackett
Franklin Volvovitz
Original Assignee
Protein Sciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Sciences Corp filed Critical Protein Sciences Corp
Application granted granted Critical
Publication of DK0830141T3 publication Critical patent/DK0830141T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK96913234T 1995-04-28 1996-04-26 Forbedrede virusvacciner DK0830141T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/430,971 US5976552A (en) 1995-04-28 1995-04-28 Virus vaccines
PCT/US1996/005904 WO1996033738A1 (en) 1995-04-28 1996-04-26 Improved virus vaccines

Publications (1)

Publication Number Publication Date
DK0830141T3 true DK0830141T3 (da) 2003-10-20

Family

ID=23709884

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96913234T DK0830141T3 (da) 1995-04-28 1996-04-26 Forbedrede virusvacciner

Country Status (12)

Country Link
US (2) US5976552A (da)
EP (1) EP0830141B1 (da)
CN (1) CN1141977C (da)
AT (1) ATE243530T1 (da)
AU (1) AU696690B2 (da)
CA (1) CA2222283C (da)
DE (1) DE69628834T2 (da)
DK (1) DK0830141T3 (da)
ES (1) ES2201184T3 (da)
HK (1) HK1013595A1 (da)
PT (1) PT830141E (da)
WO (1) WO1996033738A1 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6485729B1 (en) * 1993-09-13 2002-11-26 Protein Sciences Corporation Neuraminidase-supplemented compositions
DE69736132T2 (de) * 1996-10-31 2007-01-11 Slk Foundation Aromatische zusammensetzung, herstellung und verwendung derselben
AU7126998A (en) * 1997-04-16 1998-11-11 Connaught Laboratories Inc. Anti-influenza compositions supplemented with neuraminidase
WO2000035481A2 (en) 1998-12-17 2000-06-22 Connaught Laboratories Limited Multivalent immunogenic composition containing rsv subunit composition and influenza virus preparation
AT407958B (de) * 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
BR0014281A (pt) * 1999-09-24 2002-05-21 Smithkline Beecham Biolog Vacina contra vìrus de gripe intranasal
US7122018B2 (en) 2000-12-26 2006-10-17 Sensormedics Corporation Device and method for treatment of wounds with nitric oxide
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
EP1551444B1 (en) 2002-10-16 2018-03-21 Samuel F. Hunter Method for treatment of demyelinating central nervous system disease using gm-csf
US20060110740A1 (en) * 2003-01-20 2006-05-25 Julia Hurwitz Use of sendai virus as a human parainfluenza vaccine
US7282353B2 (en) * 2003-08-19 2007-10-16 Academia Sinica Protein isolation
MY157941A (en) 2005-01-19 2016-08-15 Vaxinnate Corp Compositions of pathogen-associated molecular patterns and methods of use
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
CN101248186A (zh) * 2005-05-23 2008-08-20 瓦克辛公司 不含腺病毒的重组腺病毒载体的快速生产
US20070116785A1 (en) * 2005-11-18 2007-05-24 Miller Christopher C Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant
US9333249B2 (en) 2006-02-09 2016-05-10 Educational Foundation Jichi Medical University Recombinant baculovirus vaccine
TWI477602B (zh) 2006-02-09 2015-03-21 Educational Foundation Jichi Medical Univ Novel viral vector
ES2534332T3 (es) 2006-03-07 2015-04-21 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
JP2010521460A (ja) * 2007-03-12 2010-06-24 アンティジェン・エクスプレス・インコーポレーテッド 癌免疫療法におけるＩｉ−ＲＮＡｉ関与Ｉｉ抑制
CN101307310B (zh) * 2007-05-15 2012-08-08 康泰生医科技股份有限公司 具有提高产率及免疫原性的重组蛋白质表达系统
EP2014279A1 (en) * 2007-06-22 2009-01-14 Pevion Biotech AG Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof
WO2009128950A2 (en) * 2008-04-18 2009-10-22 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
SG182305A1 (en) * 2010-01-06 2012-08-30 Vaxinnate Corp Methods and compositions for providing protective immunity in the elderly
US20130115237A1 (en) 2010-06-09 2013-05-09 Vaccine Technologies, Incorporated Therapeutic immunization in hiv infected subjects to augment antiretroviral treatment
AP2013006835A0 (en) * 2010-11-02 2013-04-30 Zepeda Lopez Hector Manuel Novel vaccines against the A/H1N1 pandemic flu virus
ES2645156T3 (es) 2011-03-21 2017-12-04 Altimmune Inc. Agente terapéutico inmunológico de acción rápida y prolongada
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
JP2019511255A (ja) 2016-01-11 2019-04-25 バーンダリ，インク． マイクロニードル組成物およびそれを使用する方法
CN105854009A (zh) * 2016-05-03 2016-08-17 重庆三杰众鑫生物工程有限公司 应用番鸭肝炎病毒制备灭活疫苗的制备方法
MX2019014943A (es) 2018-12-12 2020-08-06 Cambridge Tech Llc Vacuna universal contra la gripe.
IL312502A (en) 2021-11-05 2024-07-01 Sanofi Sa Hybrid multivalent influenza vaccines containing hemagglutinin and neuraminidase and methods of using them
IL312545A (en) 2021-11-05 2024-07-01 Sanofi Pasteur Inc Multivalent Influenza Vaccines Including Hemagglutinin and Recombinant Neuraminidase and Methods of Using Them

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2667245B1 (fr) * 1990-10-01 1992-11-06 Rhone Merieux Association vaccinale contre les pathogenes infectieux.
CA2139756A1 (en) * 1992-07-08 1994-01-20 Eric M. Bonnem Use of gm-csf as a vaccine adjuvant

Also Published As

Publication number Publication date
EP0830141B1 (en) 2003-06-25
ES2201184T3 (es) 2004-03-16
WO1996033738A1 (en) 1996-10-31
PT830141E (pt) 2003-11-28
EP0830141A1 (en) 1998-03-25
CN1189103A (zh) 1998-07-29
AU696690B2 (en) 1998-09-17
CN1141977C (zh) 2004-03-17
DE69628834T2 (de) 2004-05-06
HK1013595A1 (en) 1999-09-03
DE69628834D1 (de) 2003-07-31
AU5631296A (en) 1996-11-18
US20020071848A1 (en) 2002-06-13
CA2222283C (en) 2015-02-03
US5976552A (en) 1999-11-02
CA2222283A1 (en) 1996-10-31
ATE243530T1 (de) 2003-07-15

Similar Documents

Publication Publication Date Title
DK0830141T3 (da) Forbedrede virusvacciner
Hashigucci et al. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin
EP0705109B2 (en) Adjuvants for vaccines against respiratory syncytial virus
AU2684792A (en) Porcine reproductive respiratory syndrome vaccine and diagnostic
FI102616B1 (fi) Menetelmä rokotteen valmistamiseksi ihmisen parainfluenssa-viruksen tyyppiä 3 varten ja menetelmässä käytettävä ilmentämisjärjestelmä
DK0584348T3 (da) Genetisk vaccine mod immundefektvirusser
RU94042722A (ru) Химерный белок, ген, клетка, вектор, способ получения химерного белка, вакцина
CA2181832A1 (en) Immunization by inoculation of dna transcription unit
RU2000116260A (ru) Вакцины с адъювантом ltb
MX9702336A (es) Composiciones de vacuna.
MX9802285A (es) Vacunas y glicoproteinas de virus de parainfluenza.
EA200000528A1 (ru) Способ получения вакцин для предупреждения патогенных эффектов, связанных с ретровирусной инфекцией
Downie Neuraminidase-and hemagglutinin-inhibiting antibodies in serum and nasal secretions of volunteers immunized with attenuated and inactivated influenza B/Eng/13/65 virus vaccines
AU3887695A (en) Interleukin-12 as an adjuvant for paramyxoviridae vaccines
ES2079851T3 (es) Uso de il-4 para mejorar la respuesta inmunitaria frente a inmunogenos en vacunas.
GB1229888A (da)
DE69720024D1 (de) Immunisierungsverfahren in zwei schritten gegen pyramyxoviridae-viren unter verwendung abgeschwächter viraler stämme und preparation von proteinuntereinheiten
IL86675A (en) Immunogen containing non- infectious hiv particles and pharmaceutical compositions containing the same
Liashenko et al. Measles IgA in the nasal washings of adult volunteers and children immunized intranasally with measles vaccine L-16
BR9909076A (pt) Vìrus atenuado do sarampo, recombinantemente gerado, isolado, vìrus do sarampo, vìrus sincicial respiratório humano (rsv), subgrupo b, atenuado, recombinantemente gerado, isolado, o rsv, subgrupo b, vacina processo para imunização de um indivìduo para induzir proteção contra vìrus do sarampo, processo para imunização de um indivìduo para induzir proteção contra o rsv, subgrupo b, composição, processo para produção de vìrus do sarampo infeccioso atenuado, processo para produção de rsv infeccioso atenuado subgrupo b
WO2001083528A3 (en) Nucleic acid immunization
PT100460A (pt) Partiiculas derivadas de virus de herpes e vacinas que as contem
Trudel et al. Efficient intranasal vaccination of mice against human respiratory syncytial virus with an experimental iscoms subunit vaccine
Reddy et al. Efficacy of a combined live attenuated canine distemper and inactivated rabies vaccine in dogs
IE45441L (en) Influenza virus vaccine.